Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,753 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07487662 | TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk(ACTION-001) | not yet recruiting | Phase 2 | 105 | Sun Yat-sen UniversityOTHER | 0 | Mar 27, 2026 | clinicaltrials |
| NCT07497204 | Splenic Artery Infusion Chemotherapy vs Systemic Chemotherapy in Advanced Pancreatic Body/Tail Cancer(SAIC-PBTC) | completed | — | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| 1 |
| Mar 27, 2026 |
| clinicaltrials |
| NCT07497958 | Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy | not yet recruiting | N/A | 174 | Sun Yat-sen UniversityOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05982821 | Artificial Intelligence-assisted Contrast-enhanced Ultrasound Diagnosis of Thyroid Nodules(AIA-CEUD-TN) | completed | N/A | 1,955 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07489703 | SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Mar 24, 2026 | clinicaltrials |
| NCT06146764 | CEUS Improves the Diagnostic Performance of SRSS of Thyroid Carcinoma | recruiting | — | 800 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07125755 | Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma | recruiting | Phase 3 | 386 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07488533 | Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma | active not recruiting | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07488572 | Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study | enrolling by invitation | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07320963 | Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. | not yet recruiting | Phase 1 / Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 0 | Mar 20, 2026 | clinicaltrials |
| NCT07483242 | Individualized Surgical Guidance in HCC-BDTT | completed | — | 151 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07479264 | A Study on Intratumoral Fibrosis and α-SMA Expression in Intrahepatic Cholangiocarcinoma | completed | — | 169 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07362979 | Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma | recruiting | Phase 2 | 243 | Sun Yat-sen UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07469956 | Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07467122 | Exploratory Clinical Study of TCR-T for MAGE-A4-positive Mesenchymal Malignancies | recruiting | Phase 1 | 15 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT06277388 | Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment. | active not recruiting | — | 231 | Sun Yat-sen UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07463677 | Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 55 | Sun Yat-sen UniversityOTHER | 0 | Mar 11, 2026 | clinicaltrials |
| NCT07463690 | Construction and Evaluation of a Flipped Discharge Model for Stomates With Colorectal Cancer | not yet recruiting | N/A | 200 | Sun Yat-sen UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02867956 | Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | completed | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04341883 | Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer | completed | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04651127 | Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer | terminated | Phase 1 / Phase 2 | 5 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05824468 | Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer | active not recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05824481 | Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer | active not recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06239727 | Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response | recruiting | Phase 3 | 593 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06071052 | TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens(DREAM) | completed | Phase 2 | 21 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06608537 | A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer | completed | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07449065 | CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC | completed | — | 324 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04127227 | Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type | active not recruiting | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT05389306 | Combining MRI and CEUS to Diagnose Small Cervical Lymph Node Metastases in NPC Patients(NPC-LN) | completed | N/A | 348 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06719700 | Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer | recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07353567 | Long-term Outcomes and Risk Factors of Local Re-Recurrence in Patients | completed | — | 298 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 0 | Mar 3, 2026 | clinicaltrials |
| NCT02767661 | Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer(MECCA) | completed | Phase 3 | 263 | Sun Yat-sen UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04945720 | Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma | completed | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07432542 | Pelvic Floor Peritoneal Closure to Prevent Postoperative Ileus in Mid-Low Rectal Cancer Surgery(TOWER-1) | active not recruiting | N/A | 516 | Sun Yat-sen UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07413146 | Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial | not yet recruiting | N/A | 100 | Sun Yat-sen UniversityOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT07415200 | Pedicled Lateral Chest Wall Lymph-Adipofascial Flap to Prevent Arm Lymphedema After Breast Cancer Surgery(LAF-ALND) | not yet recruiting | N/A | 100 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07415980 | Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL | not yet recruiting | Phase 1 / Phase 2 | 68 | Sun Yat-sen UniversityOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT07408648 | A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy | not yet recruiting | Phase 2 | 244 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Feb 13, 2026 | clinicaltrials |
| NCT06517511 | Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) | recruiting | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07405736 | Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 124 | Sun Yat-sen UniversityOTHER | 0 | Feb 12, 2026 | clinicaltrials |
| NCT06253065 | Prospective Validation of Pathology-based Artificial Intelligence Diagnostic Model for Lymph Node Metastasis in Prostate Cancer | completed | — | 225 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07402538 | Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma | not yet recruiting | Phase 3 | 184 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07398638 | Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study | not yet recruiting | Phase 1 / Phase 2 | 122 | Sun Yat-sen UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07401537 | Efficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer | recruiting | Phase 2 | 416 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07401641 | Effect of Dezocine Versus Nalbuphine Combined With Sufentanil on Postoperative Analgesia, Complications, and Free Flap Survival in Patients Undergoing Oral Cancer Radical Surgery: A Randomized Controlled Clinical Trial. | recruiting | N/A | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07401654 | The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression | not yet recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Feb 10, 2026 | clinicaltrials |
| NCT05430698 | PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma | recruiting | Phase 2 | 62 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07388758 | Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389629 | Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | recruiting | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials